Approval · Notice of Compliance 34449 · 2024
WEGOVY: Notice of Compliance 34449
Issued November 25, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34449
- Date
- November 25, 2024
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication: to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| WEGOVY | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 0.25 MG per 0.5ML
- SEMAGLUTIDE 0.5 MG per 0.5ML
- SEMAGLUTIDE 1 MG per 0.5ML
- SEMAGLUTIDE 1.7 MG per 0.75ML
- SEMAGLUTIDE 2.4 MG per 0.75ML
- SEMAGLUTIDE 1 MG per 1.5ML
- SEMAGLUTIDE 2 MG per 3ML
- SEMAGLUTIDE 2 MG per 1.5ML
- SEMAGLUTIDE 4 MG per 3ML
- SEMAGLUTIDE 6.8 MG per 3ML
- SEMAGLUTIDE 9.6 MG per 3ML